RE: Slides out28 Apr 2022 19:26
could AZN be in the mix for 737 as well, looking at this RNS,?
and has the AZD 5153 they are referring to in this RNS turned into the SRA515
that they are selling to GSK? a bidding war is coming for the rights to 737 IMO,
everything else is just a smoke screen...
and with P2 been completed in solid Tumor thus far, perhaps that's what they are all after
as its the hardest Cancer to get rid off, FK everything else..
''ANYWAY'' that strange news in 2021......
Cambridge, UK, 6 August 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), held an investor call last night at 10pm BST to discuss its newly announced global in-licensing agreement with AstraZeneca for AZD5153, a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.
In discussing the rationale for adding AZD5153 to its pipeline, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications, through potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action.
its getting very interesting here
ATB
308..